Introduction
Among all gynecological malignancies, ovarian cancer remains the most lethal. There are no early detection tests, so that the disease is diagnosed at an advanced stage (NIH Consensus Statement, 1994) . Like other processes of human tumorigenesis, ovarian carcinogenesis is a multistep process activated by multiple oncogenes or inactivated by tumor suppressor genes. Overexpression of c-erb-B2 (Meden et al., 1995) , expression of mutant tumor suppressor gene p53 (Henriksen et al., 1994) , Bcl-2 (Marx et al., 1997) , mutant BRCA1 and BRCA2 (Rauh-Adelmann et al., 2000) have been reported in patients with family histories of ovarian cancer.
Dierentially expressed genes in normal and cancer cells have recently been identi®ed in order to ®nd novel tumor markers and understand the pathways of cancer development and progression. cDNA microarray is an eective high-throughput method of examining largescale dierential gene expression patterns of speci®c cDNA populations on a single blot (DeRisi et al., 1996) . Fuller et al. (1999) successfully used this approach to determine that insulin-like growth factor binding protein 2 (IGFBP2) is overexpressed in glioblastoma multiforme, and Huang et al. (2000) identi®ed superoxide dismutase as a target for the selective killing of cancer cells. An alternative method of gene-expression pro®ling is the serial analysis of gene expression (SAGE) (Velculescu et al., 1995; Zhang et al., 1997; Hough et al., 2000) . An eort to pro®le gene expression using SAGE was launched by NCBI, and a public database is available for increasing numbers of normal and neoplastic human cell lines and tissues (http://www.sagenet.org).
In this study, we used the cDNA expression array to analyse gene expression in tissue from normal and neoplastic ovaries. Putative candidate genes were con®rmed by polymerase chain reaction (PCR) and Northern blot analysis and selected for further characterization. Our results suggested that thymosin b-10 is downregulated in human ovarian cancer and may play an important role in human ovarian carcinogenesis. tissues, we identi®ed several genes whose expressions were changed, as marked by arrows in Figure 1 , no signal was visible in blank spots and negative control spots (M13 DNA, lphage DNA, and pUC18 DNA), indicating that the hybridization was highly speci®c. Expression levels of speci®c genes, either increased or decreased, were quanti®ed by densitometric scanning of hybridized signals. The quanti®cation results are summarized in Tables 1 and 2 . Only genes with expression levels that were altered more than twofold in comparisons of normal and cancer samples, and in more than two of the ovarian cancer samples, are included. Gene expression was normalized to that of housekeeping gene GAPDH. Similar expression patterns for these genes were obtained in independent cDNA array hybridization experiments.
Six genes showed increased expression in ovarian cancer tissues: Mothers against DPP protein (Smad1), prothymosin alpha, Tob, C-1, heat shock 27-kDa protein 1, and insulin-like growth factor IA (Table   1 ). The expression of 12 genes was decreased in ovarian cancer tissues, including a group of apoptosis-related proteins, DNA-binding proteins, DNA-binding protein inhibitors, transcription factors and thymosin b-10 (Table 2) . Among them, thymosin b-10 showed consistently decreased expression levels in four of ®ve cancer samples. To validate this observation, we examined thymosin b-10 expression by Northern blotting. As shown in Figure 2 , Northern blotting analysis con®rmed decreased thymosin b-10 mRNA levels in four of ®ve ovarian tumors. We also performed PCR analysis of thymosin b-10 with two commercially available matched human ovarian cDNA pairs (tumor versus normal; Clontech Laboratories, Palo Alto, CA, USA) as templates. The result showed that thymosin b-10 was decreased in cancer cells in one of the two pairs (Figure 2c ). Thymosin b-10 expression was found to be highest in normal ovary compared with other organs examined, including spleen, thymus, prostate, testis, small intestine, colon and peripheral blood leukocytes ( Figure 2 ). To further con®rm the expression pattern of thymosin b-10 in ovarian cancer versus normal cells, we analysed the data of its expression in the ovarian SAGE libraries available at the NCBI database (Hough et al., 2000) and an ovarian SAGE library we built (Hu et al., unpublished results). For SAGE analysis, the frequencies of tags represent the relative expression of the genes in the cell population. As shown in Table 3 , similar frequencies for thymosin b-10 were seen in a normal ovarian epithelial cell line, an SV40 large T antigen-transformed ovarian epithelial cell line, and three of the 10 tumors, whereas lower frequencies were found in six of the 10 tumors; in one tumor, the frequency of thymosin b-10 expression was increased. These observations suggested that thymosin b-10 is downregulated in approximately 60% of ovarian cancers and may play an important role in the development of this subset of ovarian cancers. To test this hypothesis, we constructed an Ad-GFP-thymosin b-10 viral vector ( Figure 3 ) and infected two human ovarian cancer cell lines, PA-1 and SKOV3 with it. Eciency of transduction was assessed using Ad5CMV-GFP, and the rate was 
Discussion
Using cDNA microarray technology to identify genes that have a major role in ovarian cancer development, we found a number of genes that showed dierential expression in normal and cancer cells of the ovary. We focused on thymosin b-10, whose expression was attenuated in four of ®ve ovarian cancer tissues. Furthermore, overexpression of the adenovirus vector containing the thymosin b-10 gene led to apoptosis and disruption of stress ®bers in ovarian cancer cells. Therefore, thymosin b-10 may play an important role in normal ovarian epithelial cell homeostasis and ovarian carcinogenesis.
Thymosin b-4, -10 and -15 act as major actin monomer-sequestering factors. Thymosin b-4 has 43 amino acids and shares a high degree of homology (85%) at the amino-acid level with thymosin b-10. A number of investigations have now suggested that the roles of thymosin b-4 and b-10 may be related to mechanisms associated with cell division and/or dierentiation. Despite these genes' structural and functional similarities, dierent expression patterns have been observed. For example, while both thymosins were strongly expressed in fetal brain and other fetal organs, thymosin b-10 levels fell considerably in most adult tissues (Hall et al., 1990 (Hall et al., , 1991 , and thymosin b-4 expression was down-regulated in metastatic cells of colorectal carcinomas (Yamamoto et al., 1993) . Another recently discovered member of the b-thymosin family, thymosin b-15, is upregulated in Thymosin b-10 gene in human ovarian cancer S-H Lee et al aggressive human prostate cancer (Bao et al., 1996) , it is expressed in highly motile, metastatic prostate cancer cells (Eadie et al., 2000) as well as in advanced human prostate and breast cancer (Bao et al., 1996; Gold et al., 1997) . Thymosin b-15 diers from other bthymosins in that its expression correlates with motility and metastasis in highly metastatic prostate carcinoma cells (Eadie et al., 2000) . Thymosin b-10 is a small actin-binding protein (Nachmias, 1993) known to sequester actin monomers and thereby induce depolymerization of the intracellular F-actin networks (Yu et al., 1993 (Yu et al., , 1994 . Actin is one of the most abundant structural proteins in the cell (Pollard and Cooper, 1986) , and the dynamic equilibrium between monomeric and ®lamentous actin is shown to be altered in neoplastic/transformed cells (Hall, 1994a,b) . Alteration of thymosin b-10 expression may thus aect the cellular infrastructure by changing the actin stress ®ber, which may further alter the balance of cell growth, cell death, cell attachment and cell migration (Yu et al., 1993) . During embryogenesis, thymosin b-10 is also highly expressed (Carpintero et al., 1996) , which is consistent with constant cell migration and morphogenesis that require cell detachment. Thymosin b-10 was also shown to be involved in inducing processes leading to cell detachment (Iguchi et al., 1998) .
Thymosin b-10 has also been proposed to have dual functions: programmed cell death (Hall, 1995) and invasion or metastasis (Verghese-Nikolakaki et al., 1996; Marian et al., 1993) . Whereas thymosin b-10 may contribute to invasion or metastasis by some cancer types, our results demonstrated its involvement in apoptosis in ovarian tissue. When thymosin b-10 was highly expressed in ovarian tumor cells via the adenovirus expression vector, we observed a high rate of cell death. Therefore, attenuation of expression of thymosin b-10 is likely to be important for ovarian cancer development, at least in a subset of ovarian cancer. Thus, restoration or overexpression of thymosin b-10 expression may represent a new strategy to treat ovarian cancers. Figure 4 Eect of thymosin b-10 on the growth of ovarian cancer cell lines PA-1 and SKOV3. Cells were plated in 6-well dishes and infected with Ad5CMV-gfp-thymosin b-10; then cell growth was measured at 1-day intervals for 3 or 4 days. At each time point, data were obtained from six separate cultures. The results are means+s.e.mean from two dependent experiments Interestingly a previous report had shown overexpression of thymosin b-10 in ovarian cancer tissue and several other cancers (Santelli et al., 1999) . Our results showed a heterogeneous level of expression, with decreased levels in a majority of cases. Upregulation of the thymosin b-10 gene in ovarian cancer seen in the previous report (Santelli et al., 1999) may have resulted from inclusion of only one normal ovarian tissue as control for 14 ovarian cancers examined. We believe that pairing of normal and ovarian tumor samples is more eective because the level of expression in normal ovarian tissue of dierent individuals may vary signi®cantly.
Ovarian cancer is a heterogeneous disease. Histologically, it may be divided into serous, mucinous, endometroid and clear-cell types. Each type of ovarian cancer may have a distinct pathway of carcinogenesis. For example, mutations in the p53 tumor suppressor gene have been found in approximately 63% of serous and in 22% of mucinous ovarian carcinomas (Morita et al., 2000) . Mutations in codon 12 of K-RAS were signi®cantly more prevalent in borderline (41%) than in malignant (11%) ovarian tumors (Cadu et al., 1999) . Therefore, the expression of thymosin b-10 could vary signi®cantly in dierent types of ovarian cancer and have dierent roles in dierent types of ovarian carcinogenesis. We intend to extend our current studies to a larger number of clinical ovarian cancers to examine whether down-or up-regulation is associated with particular histologic characteristics or a speci®c subset of ovarian cancer, with distinct clinical outcomes.
Materials and methods

Tissues and RNA isolation
Ovarian cancer tissues were obtained from patients of the Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea. The disease stage of the tissue sample was assigned according to the classi®cation proposed by the clinical staging criteria of the International Federation of Gynecology and Obstetrics (FIGO). Five pairs of normal and ovarian cancer tissues were used: one papillary serous adenocarcinoma (stage IIIc), one borderline mucinous ovarian tumor (stage Ic), one serous cystadenocarcinoma (stage IIIc) and two clear-cell carcinomas (stage Ic). The tissues were frozen in liquid nitrogen and stored at 7708C. Before RNA extraction, a part of each tissue sample was sliced by paran section and examined by hematoxylin and eosin staining. Tissue samples containing more than 50% tumor cells were used in this study. We obtained paired normal tissues from uninvolved ovaries for each individual patient, microscopically examining them to con®rm that the tissue contained no malignant cells.
Total RNAs were obtained by extracting tissues in Trizol (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer's instructions. Normal ovarian tissues and ovarian cancer tissues (about 100 mg of each) were homogenized in Trizol solution (1 ml) using a Polytron homogenizer (Brinkman, Switzerland). Homogenates were incubated for 10 min on ice, and 0.2 volumes of chloroform was added to the homogenates. After vigorous agitation for 5 min, the inorganic phase was separated by centrifugation at 12 000 g for 20 min at 48C. RNAs were then precipitated in the presence of one volume of isopropanol. RNA pellets were washed with 70% ice-cold ethanol, then dissolved in RNasefree water. Total RNA concentration was assessed by absorbency at 260 nm using an ultraviolet spectrophotometer (Biochrom LKB, UK).
cDNA synthesis and hybridization 32 P-labeled cDNAs were synthesized with the use of total RNA from both normal and tumor tissues by reverse transcription in the presence of [ 32 P]dCTP. Brie¯y, total RNAs (20 mg each) were denatured at 758C for 10 min in the presence of 8 pmol of dT 15 VN (V=A, G and C; N=A, G, C and T) mixture. After the denaturation step, cDNAs were synthesized by incubation at 378C for 1 h in a master mix (total reaction volume, 40 ml) containing 3 ml of dNTP (500 mM, without dCTP), 5 ml [ 32 P]dCTP (3000 Ci/mmol; Amersham Life Science, Cleveland, OH, USA), and 1600 U of MMLV reverse transcriptase (Promega, Madison, WI, USA) in 16RT buer (supplied by Promega). The reaction was terminated by heating for 10 min at 758C, and unincorporated nucleotides were removed by gel puri®cation (Chroma spin-200; Clontech). For each reaction, about 2610 7 c.p.m. was incorporated in the ®nal product. After gel puri®cation, labeled cDNAs were denatured by boiling for 5 min and then hybridized to Atlas 1 human cDNA array blots (Clontech; http://www.clontech.com/atlas/genelists/Hbroad.txt) in hybridization solution (ExpressHyb hybridization solution, Clontech). Membranes were prehybridized at 688C for at least 2 h before probe addition. Hybridization was performed at 688C in a rolling bottle overnight. After the ®rst two washes with 26SSC (16SSC: 0.15 M NaCl, 15 mM sodium citrate, pH 7.0) and 0.1% SDS at 688C for 20 min, the membranes were subjected to a stringent wash with 0.16SSC, 0.5% SDS, and 0.1 mM EDTA at 688C. Membranes were then exposed to X-ray ®lm (Hyper®lm, Amersham) for 1 or 3 days at 7708C. To normalize the relative gene expression, we selected the GAPDH and ribosomal protein S9 gene as internal references.
Northern hybridization
For Northern blot hybridization, total RNA (10 mg) was denatured in the presence of 50% formamide, 2.2 M formaldehyde, 20 mM MOPS (3-[N-morpholino] propanesulfonic acid), 4 mM sodium acetate and 0.5 mM EDTA at 658C for 10 min. After electrophoresis in a 1.2% agarose gel containing 2.2 M formaldehyde, RNA was transferred onto a nylon membrane (Nytran, 0.45-mm pore size; Schleicher and Schuell, Germany) by capillary action under 106SSPE 16SSPE: 0.18 M NaCl, 10 mM Na 2 HPO 4 [pH 7.7], 1 mM EDTA). RNA transfer and loading eciency was estimated by staining a separate membrane with 0.1% methylene blue. RNA intactness was estimated by comparing the intensities of the 28S and 18S ribosomal RNA bands. For hybridization, the membrane was washed in 66SSPE for 5 min and air-dried, and the RNA was permanently attached to the membrane by UV illumination for 1 min. Hybridization was performed overnight in a heat-sealable polyethylene bag containing 40 ml of hybridization buer (56SSPE [pH 7.4], 56Denhardt's solution, 0.5% SDS, 0.2 mg/ml heat-denatured salmon sperm DNA, 50% formamide) and the hybridization probe. The thymosin b-10 cDNA (178 bp) probe containing the entire coding sequences was obtained by PCR ampli®cation with Tb5'-(CGGGCTCGGAACGA-GAGT) and Tb3'-(GGATCTTAGGAAATTTCACTCCGC). 32 P-labeled cDNA probes were synthesized using a Rediprime cDNA synthesis kit (Amersham).
Polymerase chain reaction
The dierential expression of thymosin b-10 was con®rmed by PCR and the human ovary 1 and 2 matched cDNA pairs (Clontech) were used as template. First pair: cDNA of ovary serous cystadenocarcinoma and normal tissue; second pair: cDNA of ovary papillary serous carcinoma and normal tissues. PCR was performed at the following cycles: 30 s at 948C; 30 cycles of 30 s at 948C; 1 min at 688C; 1 min at 728C; 5 min at 728C, according to the manufacturer's protocols (Clontech). We used 5'-TCGGAACGAGACTGCACG-GATTGT and 3'-CCGGAGAATTTGGCAGTCCGATTG primers for thymosin b-10, and we used human ribosomal protein S9 5'-GATGAGAAGGACCCACGGCGTCTGT-TCG and 3'-GAGACAATCCAGCAGCCCAGGAGGGA-CA primers as control.
Construction and transfection of Ad-GFP-thymosin b-10
PCR-ampli®ed, full-length human thymosin b-10 fragment (349 bp) was cloned into pCRII-TOPO vector. The primers used to generate the full-length were 5'-CGGGCTCGGAAC-GAGACT and 3'-ATTTGGCAGTCCGATTGG. The cloning product was con®rmed for sequence from both directions. The pCR-TOPO-thymosin b-10 was digested with EcoRI and cloned into the pDACMV EcoRI site. The 0.4-kb BamHI fragment of thymosin b-10 was inserted into the BglII site of pQBI-Ad5CMV-GFP vector (Quantum, Canada). The Ad-GFP-thymosin b-10 construct was used at 100 M.O.I. for all transfection experiments.
Western blotting
Cells were lysed and equal amounts of cell extracts (10 mg) were electrophoresed on 15% SDS polyacrylamide gel, electrotransferred onto a nitrocellulose membrane, probed with rabbit anti-thymosin b-10 antibody (provided by Dr Leondiadis L, Institute of Radioisotopes and Radiodiagnostic Products, NCSR Demokritos, Athens, Greece). Detection was performed using the enhanced chemiluminescence system (Amersham).
Cell-counting assay
Cells were plated in triplicate at a density of 2610 5 cells/well in 6-well plates. Twenty-four hours later, the cells were infected with Ad-GFP-thymosin b-10. Beginning 24 h after infection, cells were harvested each day, stained with Trypanblue and counted with the light microscope for up to 3 days (PA-1) or up to 5 days (SKOV3).
Apoptosis assay
Cells were plated onto 4-chamber slides (Nalgen Nunc, Inc., Naperville, IL, USA) at densities of 5610 4 cell/well and cultured for 1 day. Two days after infection with Ad-GFPthymosin b-10 and Ad-GFP, chamber slides were rinsed with phosphate-buered saline (PBS), stained with 2 mg/ml of DAPI; (Boehringer Mannheim) at 378C for 15 min, washed twice with PBS and examined with the¯uorescence microscope.
Fluorescence detection of F-actin
Cell monolayers were ®xed for 40 min at room temperature with 4% paraformaldehyde in PBS and then stained with phalloidin-FITC (Sigma) (25 mg/ml) for 1 h in the dark. Stained cell monolayers were washed twice with 0.5% Triton X-100 in PBS; coverslips were mounted onto slides using a PBS/glycine mountant and examined with the¯uorescence microscope.
